Literature DB >> 11972360

Endocannabinoids and neuroprotection.

R Mechoulam1, M Spatz, E Shohami.   

Abstract

Traumatic brain injury (TBI) releases harmful mediators that lead to secondary damage. On the other hand, neuroprotective mediators are also released, and the balance between these classes of mediators determines the final outcome after injury. Recently, it was shown that the endogenous brain cannabinoids anandamide and 2-Arachidonoyl glycerol (2-AG) are also formed after TBI in rat and mouse respectively, and when administered after TBI, they reduce brain damage. In the case of 2-AG, better results are seen when it is administered together with related fatty acid glycerol esters. Significant reduction of brain edema, better clinical recovery, and reduced infarct volume and hippocampal cell death are noted. This new neuroprotective mechanism may involve inhibition of transmitter release and of inflammatory response. 2-AG is also a potent modulator of vascular tone, and counteracts the endothelin (ET-1)-induced vasoconstriction that aggravates brain damage; it may thus help to restore blood supply to the injured brain.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11972360     DOI: 10.1126/stke.2002.129.re5

Source DB:  PubMed          Journal:  Sci STKE        ISSN: 1525-8882


  50 in total

Review 1.  [Cannabinoids--signal transduction and mode of action].

Authors:  R Rukwied; B Gauter; M Schley; C Konrad
Journal:  Schmerz       Date:  2005-11       Impact factor: 1.107

2.  Reduced infarct size and accumulation of microglia in rats treated with WIN 55,212-2 after neonatal stroke.

Authors:  D Fernández-López; J Faustino; N Derugin; M Wendland; I Lizasoain; M A Moro; Z S Vexler
Journal:  Neuroscience       Date:  2012-01-12       Impact factor: 3.590

3.  Forebrain-specific inactivation of Gq/G11 family G proteins results in age-dependent epilepsy and impaired endocannabinoid formation.

Authors:  Nina Wettschureck; Mario van der Stelt; Hiroshi Tsubokawa; Heinz Krestel; Alexandra Moers; Stefania Petrosino; Günther Schütz; Vincenzo Di Marzo; Stefan Offermanns
Journal:  Mol Cell Biol       Date:  2006-08       Impact factor: 4.272

Review 4.  Endocannabinoids and cannabinoid receptors in ischaemia-reperfusion injury and preconditioning.

Authors:  P Pacher; G Haskó
Journal:  Br J Pharmacol       Date:  2007-11-19       Impact factor: 8.739

5.  Cannabinoid-2 receptor agonist HU-308 protects against hepatic ischemia/reperfusion injury by attenuating oxidative stress, inflammatory response, and apoptosis.

Authors:  Mohanraj Rajesh; Hao Pan; Partha Mukhopadhyay; Sándor Bátkai; Douglas Osei-Hyiaman; György Haskó; Lucas Liaudet; Bin Gao; Pál Pacher
Journal:  J Leukoc Biol       Date:  2007-07-25       Impact factor: 4.962

6.  Hippocampal cannabinoid-1 receptor upregulation upon endothelin-B receptor deficiency: a neuroprotective substitution effect?

Authors:  Christian Unzicker; Heike Erberich; Gabriella Moldrich; Helge Woldt; Jan Bulla; Raphael Mechoulam; Hannelore Ehrenreich; Anna-Leena Sirén
Journal:  Neurochem Res       Date:  2005-10       Impact factor: 3.996

Review 7.  The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications.

Authors:  Lydia K Miller; Lakshmi A Devi
Journal:  Pharmacol Rev       Date:  2011-07-13       Impact factor: 25.468

8.  CB1 cannabinoid receptors increase neuronal precursor proliferation through AKT/glycogen synthase kinase-3beta/beta-catenin signaling.

Authors:  Stefania Trazzi; Martin Steger; Valentina Maria Mitrugno; Renata Bartesaghi; Elisabetta Ciani
Journal:  J Biol Chem       Date:  2010-01-18       Impact factor: 5.157

Review 9.  The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities.

Authors:  Tamás Bíró; Balázs I Tóth; György Haskó; Ralf Paus; Pál Pacher
Journal:  Trends Pharmacol Sci       Date:  2009-07-14       Impact factor: 14.819

Review 10.  Cannabinoids and gliomas.

Authors:  Guillermo Velasco; Arkaitz Carracedo; Cristina Blázquez; Mar Lorente; Tania Aguado; Amador Haro; Cristina Sánchez; Ismael Galve-Roperh; Manuel Guzmán
Journal:  Mol Neurobiol       Date:  2007-06-28       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.